TD Private Client Wealth’s Integra LifeSciences IART Stock Holding History

TD Private Client Wealth’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-559	Closed	-$19.8K	–	1232
2024 Q1	$19.8K	Sell	559 -228	-29%	-$9.12K	﹤0.01%	952
2023 Q4	$34.3K	Buy	787 +160	+26%	+$6.3K	﹤0.01%	881
2023 Q3	$23.9K	Hold	627	–	–	﹤0.01%	908
2023 Q2	$25.8K	Sell	627 -574	-48%	-$27.6K	﹤0.01%	907
2023 Q1	$68.9K	Sell	1,201 -120	-9%	-$6.76K	﹤0.01%	711
2022 Q4	$74.1K	Buy	1,321 +605	+84%	+$30.8K	﹤0.01%	667
2022 Q3	$30.3K	Hold	716	–	–	﹤0.01%	832
2022 Q2	$38.7K	Hold	716	–	–	﹤0.01%	781
2022 Q1	$46K	Buy	+716	New	+$47.1K	﹤0.01%	788

Other funds holding IART

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

TD Private Client Wealth's IART Position: Q2 2024 in Review

TD Private Client Wealth sold out of Integra LifeSciences (IART) in Q2 2024, closing a stake of 559 shares — an estimated $19.8K sold.

TD Private Client Wealth first reported a position in IART in Q1 2022 and held it in 9 quarters. The position peaked at $74.1K in Q4 2022. 238 funds tracked by Wall St. Rank hold IART as of Q2 2024.

TD Private Client Wealth reported no remaining Integra LifeSciences position as of Q2 2024 after selling out during the quarter.
TD Private Client Wealth sold 559 Integra LifeSciences shares in Q2 2024, an estimated $19.8K.
TD Private Client Wealth first reported a position in Integra LifeSciences in Q1 2022 and held it in 9 quarters.
TD Private Client Wealth's Integra LifeSciences position peaked at $74.1K in Q4 2022.
238 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2024.

Based on TD Private Client Wealth's 13F filing for Q2 2024, filed 14 Aug 2024.